Sagimet Biosciences reports Q4 EPS (50c), consensus (63c)

“2024 was a highly productive year for Sagimet, and we’re carrying that momentum into a strong start for 2025,” said David Happel, Chief Executive Officer of Sagimet. “We are pleased to have initiated our Phase 3 denifanstat program in MASH, with site activation and patient pre-screening underway and patient screening expected to begin soon. With the successful Phase 2b FASCINATE-2 results we reported in 2024, and Breakthrough Therapy designation granted by the FDA, we are confident in denifanstat’s potential to address the significant unmet need for patients living with MASH. At the same time, we are excited to advance a second Fatty Acid Synthase inhibitor, TVB-3567, into the clinic for the potential treatment of moderate to severe acne, following IND clearance. Given the potential of FASN inhibition across multiple disease states, we look forward to progressing both denifanstat and TVB-3567 in the coming year.”